Ferring Pharmaceuticals has announced that it has reacquired desmopressin acetate (DDAVP), which is approved as a nasal spray and a number of other formulations, from Sanofi. Ferring originally developed desmopressin, which is a synthetic form of vasopressin and is used to reduce frequent urination among other conditions.
In 2007, the FDA announced that the intranasal formulation of desmopressin was no longer indicated for the treatment of bed wetting after reports of deaths and seizures caused by hyponatremia in children who were using the drug.
Ferring President & CO Aaron Graff commented, “The return of DDAVP to its roots at Ferring is a welcome addition to our portfolio of products and affirms our commitment to supporting a wide range of disorders with high unmet medical need. As a result of this acquisition, distribution of DDAVP will be transferred from Sanofi to Ferring immediately.”
Read the Ferring press release.
